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Abstract: Murine g-aminobutyric acid (GABA) type A ho-
momeric receptors made of b1 subunits are profoundly
different, when expressed in Xenopus oocytes, from b3
homomeric receptors. Application of the intravenous
general anesthetic pentobarbital, etomidate, or propofol
to b3 homomeric receptors allows current flow. In con-
trast, b1 homomers do not respond to any of these
agents. Through construction of chimeric b1/b3 recep-
tors, we identified a single amino acid that determines the
pharmacological difference between the two b subunits.
When the serine residue present in the wild-type nonre-
sponsive b1 subunit is replaced by an asparagine found
in the same position in the b3 subunit, the resulting point-
mutated b1S265N forms receptors responsive to intrave-
nous general anesthetics, like the wild-type b3 subunits.
Conversely, after mutation of the wild-type b3 to
b3N265S, the homomeric receptor loses its ability to
respond to these same general anesthetics. Wild-type-
to-mutant titration experiments showed that the nonre-
sponsive phenotype is dominant: A single nonresponsive
residue within a pentameric receptor is sufficient to ren-
der the receptor nonresponsive. In a1bx or a1bxg2 het-
eromeric receptors, the same residue manifests as a
partial determinant of the degree of potentiation of the
GABA-induced current by some general anesthetics. The
location of this amino acid at the extracellular end of the
second transmembrane segment, its influence in both
homomeric and heteromeric receptor function, and its
dominant behavior suggest that this residue of the b
subunit is involved in an allosteric modulation of the
receptor. Key Words: GABAA receptor—b subunit—Gat-
ing—Chimera—Site-directed mutagenesis—Intravenous
general anesthetics.
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g-Aminobutyric acid (GABA) type A (GABAA) re-
ceptor is a member of the ligand-gated ion channel
superfamily of homologous receptors (Schofield et al.,
1987). Binding of the ligand, GABA, to the receptor
opens the integral Cl2 channel, driving the membrane
potential toward the chloride equilibrium potential, thus
reducing the sensitivity of the membrane to the effects of
excitatory neurotransmitters. GABA and competitive
GABA agonists such as muscimol, as well as antagonists
such as bicuculline, bind to the extracellular N-terminal
region of both the a subunit (Sigel et al., 1992) and the
b subunit (Amin and Weiss, 1993). Similarly, benzodi-
azepines bind to the N-terminal region of the g subunit
(Mihic et al., 1994). General anesthetic drugs of diverse
chemical structures, e.g., pentobarbital, propofol, etomi-
date, and volatile agents such as halothane, directly open
the GABAA Cl2 channel in the absence of GABA
(Franks and Lieb, 1994). The site on the receptor where
these drugs act has not been identified, but recent evidence
suggests a critical role of the second transmembrane seg-
ment (M2) in the action of volatile general anesthetics,
alcohol, and etomidate on GABAA receptors (Belelli et al.,
1997; Mihic et al., 1997; Moody et al., 1997).
The GABAA receptor is usually considered to be a
pentamer, consisting of five homologous subunits of at
least five types, a, b, g, d, and e, each of which has
several isoforms. The most common subunit composition
of the GABAA receptor is 2a:2b:g (McKernan and
Whiting, 1996). However, when b subunits are ex-
pressed alone, functional homomeric channels are
formed. The properties of murine b1 homomeric chan-
nels are different from those of b3 channels (Cestari
et al., 1996; Krishek et al., 1996; Davies et al., 1997;
Wooltorton et al., 1997). In b3, but not b1, homomers
pentobarbital generates a robust current that retains sev-
eral pharmacological characteristics of both native and
recombinant heteromeric receptors (Cestari et al., 1996;
Davies et al., 1997). Similarly, etomidate (Evans and
Hill, 1978; Yang and Uchida, 1996) and propofol (Hara
et al., 1993), two other intravenous general anesthetics
known to open chloride channels, also induced currents
in b3 but not b1 homomers. Because of the previously
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demonstrated importance of M2 in the action of general
anesthetics and other GABAA allosteric modulators
(Wafford et al., 1994; Stevenson et al., 1995; Thompson
et al., 1999), we investigated whether the difference in
general anesthetic pharmacology between b1 and b3
subunit homomers can be explained by divergent amino
acids in this region of the subunits.
MATERIALS AND METHODS
cDNA clones
The murine GABAA receptor a1 (Wang et al., 1992) and b1
and b3 subunit (Kamatchi et al., 1995) cDNA clones were a gift
of Dr. David R. Burt (University of Maryland Medical School).
After restriction enzyme mapping to confirm the identity of the
clones, the inserts were excised from the original pGEM (7z)
vector using EcoRI and subcloned into a modified pBluescript
plasmid (Stratagene), pMXT (a gift from Dr. Aguan Wei,
Washington University Medical Center). The multiple cloning
site of this vector is flanked by the 59 and 39 untranslated
sequences of the Xenopus globin gene for increased stability of
the mRNA (Gurdon et al., 1973). The numbering of amino
acids is based on the mature subunit peptide resulting after
cleavage of the signal peptide sequence (Kamatchi et al., 1995).
Construction of chimeric subunits
The b1 and b3 subunit cDNA clones were cut by restriction
enzymes and then spliced to produce chimeric b1/b3 subunits, in
which a region of one subunit was replaced by the corresponding
region of the other. Because no useful restriction enzyme sites
were common to both subunits, six restriction enzyme sites natu-
rally present in one or the other subunit were selected, based on
their relative locations along the sequence and convenience of use
during subcloning. Correspondingly located restriction enzyme
sites were then introduced as silent mutations in the other subunit
clone using PCR mutagenesis (Vallette et al., 1989).
PCR primers containing the necessary mutations were ob-
tained from GibcoBRL (Life Technologies) and are listed in
Table 1. These primers were used to amplify the corresponding
regions of linearized pMXT containing the b1 or b3 cDNA
clones. PCR was performed using the Expand High Fidelity
PCR kit (Boehringer Mannheim). High amounts of DNA tem-
plate and low cycle number in the reaction protocol were also
used to reduce PCR-introduced errors. PCR-amplified DNA
was subcloned using the PCR-Script SK(1) Cloning Kit (Strat-
agene) following the manufacturer’s recommended protocol.
The subcloned PCR-mutated DNA fragment was restriction
enzyme-digested and ligated into the corresponding region of
the original pMXT containing the b subunit cDNA clone. In
most cases, an additional subcloning step was performed to
minimize the size of PCR-amplified DNA fragment incorpo-
rated into the final chimera. After the final subcloning step,
each chimera was sequenced in an automated sequencer (Ap-
plied Biosystems) to verify that the fragments were correctly
spliced and to check for the absence of unintended errors.
For chimera I, a PCR mixture [5 ml of 103 buffer with
MgCl2, 4 ml of deoxynucleotide triphosphates (250 mM each),
and 0.5 ml of Taq polymerase (3.5 U/ml) in a total volume of 50
ml] was assembled using the linearized b1-pMXT cDNA clone
as template (200 ng) with primers B1BAMHI59 and B1XHOI39
(500 mM each). After mixing and spinning, two drops of
mineral oil were added to the tube, and the reaction was
performed for 15 cycles in a thermal cycler (94°C for 30 s,
62°C for 45 s, 72°C for 45 s). The PCR-amplified DNA (520
bp) was electrophoresed in 1% agarose gel, recovered with the
QIAEX DNA isolation system (Qiagen), and subcloned into the
PCR-Script SK(1) using the manufacturer’s suggested proto-
col. After confirming the identity and orientation of the insert
by restriction enzyme analysis, purified plasmid DNA was
digested with BamHI, and the fragment obtained, extending
from the mutated BamHI site to the vector BamHI site, was
subcloned into the b3-pMXT plasmid (after BamHI digestion
and dephosphorylation). The resulting intermediate plasmid
was then cut by XhoI (present in the vector upstream to the
coding sequence) and BstXI (site present in the wild-type b1
sequence), and the insert was subcloned into b1-pMXT (also
cut by XhoI and BstXI) to form chimera I, with a 359-bp DNA
segment of PCR origin. Other chimeras were created in a
similar manner from PCR products resulting from the primer
pairs listed in Table 1.
Single amino acid mutants
Point mutations were introduced by two-round PCR mutagen-
esis (Vallette et al., 1989). This technique allows the introduction
TABLE 1. Primers used for construction of chimeric subunits and size of PCR fragments incorporated into the final construct
Chimera
no. Forward primer Reverse primer PCR size and sites
I TTCTGGGATCCCATTAAATCTGACCC TGCGACTCGAGCTGCAGATGCATCATAGT 359 bp, BamHIa–BstXI
II AAATTGAGCTCCCCCAATTTTCAATTGTT TGCGACTCGAGCTGCAGATGCATCATAGT 254 bp, SacIa–SauI
III CTGCAGCTCGAGTCGCACTAGGAATCAC GTAATACGACTCACTATAGGGCb 55 bp, XhoIa–SauI
IV AATTAACCCTCACTAAAGGGc TGCGACTCGAGCTGCAGATGCATCATAGT 160 bp, BstXI–XhoIa
V ACGGGAATATTCTATTAGCACCGATGGAT GTAATACGACTCACTATAGGGCb 321 bp, SspIa–NotId
VI CGCAGGCGCGCCTCACAGCTCAAAATCAAA GTAATACGACTCACTATAGGGCb 129 bp, BssHIIa–NotId
VII AAAAAGCTTGCGAGCAAACAAGACCAG GTAATACGACTCACTATAGGGCb 160 bp/404 bp, BstXI–
XhoIa and HindIIIa–
NotId
The chimera numbers correspond to the schematic shown in Fig. 2. Actual nucleotides mutated are shown in bold, and the restriction enzyme sites
thus created are underlined. The restriction enzyme sites used to subclone the PCR-amplified fragments and the final size of the PCR-derived
fragments are also given.
a Mutated restriction enzyme site.
b T7 primer in the 39 end of the vector.
c T3 primer in the 59 end of the vector.
d NotI restriction enzyme site in the multiple cloning site 39 to the insert.
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of mutations at any region of a PCR fragment by performing two
consecutive PCR procedures. In the first round, two PCR products
are made that overlap in the region where a mutation is to be
introduced. The second round uses the products of the first round
as templates and generates a fragment that is the sum of the two
overlapping products. This secondary PCR-amplified DNA was
subcloned into PCR-Script as described for the construction of the
chimeras, and the smallest possible fragment was subcloned into
the wild-type subunits. For the b1S265N mutant, two first-round
PCR assays were assembled using chimera II as template with
primers B1SACI59 and B1S265N39, and a separate reaction was
set up using chimera VI as template and the primers B1S265N59
and B3MLU39. The PCR products of these two first-round assays
were used as templates for the second-round reaction with the
primers B1SACI59 and B3MLU39 (outside primers) following the
same protocol of the PCR assay for chimera I. The DNA fragment
amplified in this reaction was digested with BstXI and Bsu36I and
directly subcloned into b1-pMXT. The final clone contained the
mutant b1S265N site and had 210 bp of PCR-amplified DNA
fragment. The oligonucleotide primers used for construction of
this and other point mutants are listed in Table 2.
Oocyte expression
Oocytes were obtained from Xenopus laevis (Nasco or Xe-
nopus I) following a protocol approved by the institutional
animal care committee. The frogs were anesthetized in 50 ml of
water containing 0.15% tricaine for 20–30 min or until the
animals did not move when positioned with the dorsal side
down. Pieces of the ovaries were removed through small inci-
sions in the abdomen. Oocytes were dissociated and defollicu-
lated by gentle shaking in calcium-free modified Barth’s me-
dium (88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.82 mM
MgSO4, 0.41 mM CaCl2, and 7.5 mM Tris-HCl, pH 7.4) with
added collagenase (1 mg/ml, type I; Sigma). After dissociation,
healthy stage V–VI oocytes were selected and used for cRNA
injection.
The cRNA was prepared using the T3 Message Machine kit
(Ambion) following the manufacturer’s recommended proto-
col. Electrophoresis on a 1% agarose gel was performed on 1 ml
of the cRNA solution and on a standard RNA sample (1 mg/10
ml; GibcoBRL), and comparison of the relative intensity of the
bands on UV illumination was used to estimate the cRNA
concentration. Injection micropipettes were fabricated using
glass capillary tubing previously immersed in dimethyldichlo-
rosilane and baked overnight at 180°C.
LiCl-precipitated cRNA was diluted to the desired concen-
tration (between 0.25 and 1 mg/ml) in sterile RNase-free water
and aspirated into a micropipette, and 50 nl was injected into
each oocyte with a microinjector (Nanoinjector; Drumond In-
struments). Injected oocytes were incubated at 18°C in modi-
fied Barth’s medium [as above with 0.33 mM Ca(NO3)2 added]
containing 100 U/ml penicillin and 100 mg/ml streptomycin,
solution was changed daily, and experiments were performed
after 48–72 h.
Electrophysiological recordings
Electrophysiological recordings were performed in a 200-ml
chamber, with an effective volume of 50 ml (controlled by the
level of the suction outlet), continuously perfused at a rate of 3
ml/min with frog Ringer’s solution (115 mM NaCl, 2 mM KCl,
1.3 mM Na2HPO4, and 1.8 mM CaCl2, pH 7.4). A separate inlet
was connected to a solenoid valve system, permitting the ap-
plication of any of 24 different drug-containing solutions. The
change from Ringer’s solution to drug-containing solution was
performed by simultaneously closing the control solution inlet
and opening the drug-containing solution inlet, with timing
synchronized with data collection and controlled by pClamp
version 5.5 software (Axon Instruments). Recording microelec-
trodes were made of borosilicate glass (outside diameter, 1.2
mm) and had a resistance of 1–3 MV when filled with filtered
3 M KCl solution. Standard two-electrode recording was per-
formed using a GeneClamp 500 amplifier (Axon Instruments),
TABLE 2. Primers used for construction of point mutants and size of PCR fragments incorporated into the final construct
Mutant Forward primer Reverse primer
PCR size and
sites
b1S265A AAATTGAGCTCCCCCAATTTTCAATTGTT GTCTCCCTGAGGTGAGTGGCGGATGGTGGTCATGGTCAG
--------------
215 bp,
BstXI–SauI
b1S265G AAATTGAGCTCCCCCAATTTTCAATTGTT GTCTCCCTGAGGTGAGTGGCCGATGGTGGTCATGGTCAG
--------------
215 bp,
BstXI–SauI
b1S265T AAATTGAGCTCCCCCAATTTTCAATTGTT GTCTCCCTGAGGTGAGTGGGTGATGGTGGTCATGGTCAG
--------------
215 bp,
BstXI–SauI
b1S265Q AAATTGAGCTCCCCCAATTTTCAATTGTT GTCTCCCTGAGGTGAGTGTTGGATGGTGGTCATGGTCAG
--------------
215 bp,
BstXI–SauI
Mutant Inside primers Outside primers
PCR size and
sites
b1S265N ACCATCAACACTCACCTCAGGGAGACT and
GTGAGTGTTGATGGTGGTCATGGTCAG
AAATTGAGCTCCCCCAATTTTCAATTGTT
and GTAATACGACTCACTATAGGGCa
215 bp,
BstXI–SauI
b1I283M TTGACATGTATCTCATGGGCTGTTTT and
TGAGATACATGTCAATCGCTTTGACG
AAATTGAGCTCCCCCAATTTTCAATTGTT
and GTAATACGACTCACTATAGGGCa
421 bp,
SauI–BssHII
b3N265S AGCACTCACCTTAGGGAGACTCTACCCAAAAb and
--------------
GTCTCCCTAAGGTGAGTGCTGATGGTTGTCATGGTGAGb
---------------
ATTTGTCCACGGAGTGACAGT and
TCAACGCGTTAACATAGTACAGCCAGT
200 bp,
XhoI–HindIII
The point mutants were constructed by either a straightforward incorporation of a base change and a unique restriction enzyme site in the primer
itself (top section) or by the two-step sequential PCR method (bottom section). Actual nucleotides mutated are shown in bold, and the restriction
enzyme sites thus created are underlined. The restriction enzyme sites used to subclone the PCR-amplified fragments and the final size of the
PCR-derived fragments are also given.
a T7 primer at the 39 end of the vector.
b Additional silent mutation introduced to create a new restriction enzyme site (dashed underline).
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with the membrane potential held at 260 mV. All drugs and
chemicals were purchased from Sigma Chemical Co. except
etomidate (Amidate; Abbott Laboratories), and propofol (Al-
drich Chemical). Experiments were performed at room temper-
ature (21–24°C).
Data analysis
Concentration–response curves were obtained by fitting a
function of the form
I/Imax 5 Cn/~Cn 1 EC50n!,
where I is the peak current attained during a drug application,
Imax is the maximal current obtained for that cell, C is the drug
concentration, n is the Hill coefficient, and EC50 is the concen-
tration giving half-maximal current. Averaged values are pre-
sented as mean 6 SEM values. Statistical significance of an
effect was determined by the two-sided t test with the criterion
set at p , 0.05.
Peak current induced by a constant concentration of pento-
barbital was frequently observed to decrease progressively on
repeated exposure, even when the interval between applications
was long (.15 min). Correction for this effect was made by
applying a standard dose of the agonist at the beginning of the
data set and after every two test applications. Corrected peak
current amplitude of the test application was calculated using
the formula
Icorrected 5 Iobserved 3 ~Io/Ij!
where Iobserved is recorded peak current amplitude value (test),
Io is the peak current amplitude obtained during the application
of the standard dose at the beginning of the data set, and Ij is the
current value obtained for the standard dose preceding the test
application (Amin et al., 1994). For quantitation of current
potentiation by pentobarbital or etomidate, the true potentiation
over additive response was calculated as percent potentiation
5 100 3 IGABA1etomidate/(IGABA 1 Ietomidate).
RESULTS
Identification of amino acids necessary for
pentobarbital activation of the GABAA b subunit
homomeric channels
Figure 1 shows the effect of GABA, pentobarbital, and
picrotoxin on homomeric b1 and b3 receptors. GABA up
to 500 mM had no effect on either type of receptor. In
contrast, 250 mM pentobarbital induced a large inward
current in the b3 homomeric receptor. At a higher pen-
tobarbital concentration (2.5 mM) the peak current was
less, and the characteristic rebound current observed on
washout back to the control solution was seen (Akaike
et al., 1985). This pentobarbital-induced current is
known to be modulated by lanthanides and zinc but not
to be blocked by the GABAA competitive antagonist
bicuculline as reported previously (Cestari et al., 1996).
The same concentrations of pentobarbital evoked no
robust inward current in the b1 homomers. Instead, we
observed a dose-dependent outward current, probably
representing the pentobarbital-induced blockade of spon-
taneously opening channels. For both subunit isoforms,
picrotoxin evoked an outward-going current, again con-
sistent with the blockade of spontaneously opening chan-
nels. In some murine b1-injected oocytes, pentobarbital
induced small inward currents (,50 nA), consistent with
previous reports on human b1 homomers (Sanna et al.,
1995). We considered these small currents to represent a
fundamentally different phenomenon and did not pursue
it further in the present study.
To locate the site determining the different functional
properties of the b1 and b3 homomers, a series of chi-
meric subunits were constructed in which a segment of
b1 cDNA was replaced by a corresponding segment of
b3 cDNA. Figure 2 shows a schematic representation of
the parent and chimeric subunits. Each chimeric subunit
was expressed as a homomeric receptor in oocytes volt-
age-clamped at 260 mV, and the response to the appli-
cation of 500 mM pentobarbital was measured. A posi-
tive response was defined as a current .50 nA (noted in
Fig. 2 by an asterisk next to the positive chimeras). To
exclude the possibility of a nonfunctional chimera, all six
chimeras were coexpressed with the a1 subunit. All
a1:b1/b3 chimeric receptors were functional, responding
to both pentobarbital and GABA (n 5 4 for each chi-
mera). Because both b1 and b3 parent subunits form
functional receptors when coexpressed with the a1 sub-
unit (Ymer et al., 1989), this result was not surprising.
Of the first six chimeras made, only chimera IV dis-
played the positive response to pentobarbital (Fig. 3). In
this chimera, the b1 sequence replaced the b3 sequence
from the beginning of M2 all the way to the C-terminal
end; this is nearly the entire second half of the subunit.
Chimera V, in which the b1 sequence replaced the b3
sequence from the middle of the second intracellular
loop between the third (M3) and fourth (M4) transmem-
brane segments to the C-terminal end, did not show a
positive response. Thus, the region of the responsive
FIG. 1. b1 and b3 homomeric receptors have distinct pharma-
cological properties. Murine GABAA receptor (top) b1-subunit or
(bottom) b3-subunit cRNA was injected into Xenopus oocytes.
At 48–72 h later, GABA, pentobarbital, or picrotoxin was applied
to oocytes (voltage-clamped at 250 mV). Currents elicited are
shown (time of application is denoted by the solid bar). Opening
of the chloride ionophore in b3 homomers induces an inward-
going (downward) current, and closing of spontaneously open-
ing channels in b1 homomers induces an outward-going (up-
ward) current. Note the difference in the recovery from picrotoxin
for the two subunit isoforms (rightmost traces).
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chimera IV not common to the nonresponsive chimera V
is required for the transfer of function. This region con-
tains 93 amino acids, of which 19 differ between the b1
and b3 sequences. To narrow further the region confer-
ring the positive response to pentobarbital, chimera VII
was made by replacing the b1 sequence between the XhoI
and HindIII sites by the corresponding b3 sequence, as
shown in Fig. 2. The transferred region had four amino
acid substitutions and two additional amino acids present
only in the b3 sequence. This chimera, when expressed
as a homomer, retained the positive response, as shown
in Fig. 3, strongly suggesting that one or more of the six
divergent amino acids were responsible for the observed
phenotypic differences.
Serine at position 265 is the functional determinant
of pentobarbital action on GABAA b subunit
homomers
Of the six discordant amino acids, those at positions
265 and 283 were selected for mutagenesis, based on
their locations at the extracellular end of M2 and M3 and
the role of the amino acid at position 265 in other
properties of the GABAA receptor. Two mutants of the
b1 subunit were constructed. In the first, denoted
b1I283M, the isoleucine at position 283 was replaced by
the b3’s methionine; b1I283M did not acquire the re-
sponse to pentobarbital (data not shown). In the second,
b1S265N, the serine at position 265 was replaced by b3’s
asparagine.
Like wild-type b3 homomeric receptors, b1S265N ho-
momers responded to pentobarbital in a concentration-
dependent manner, with a decreased peak current at high
concentrations and an “off-response” on beginning of
washout, as shown in Fig. 4A. Figure 4B shows the best
fit of the normalized responses to the Hill equation, with
values for nH of 1.7 6 0.2 and EC50 of 38.2 6 3.7 mM
(solid line) comparable to the wild-type b3 response
(dotted line). Also like the b3 wild-type, b1S265N re-
sponded to etomidate and propofol (Fig. 5). To ensure
that the converse mutation of the b3 homomer would
convert its phenotype to the b1 type, we generated the
mutant b3N265S. Figure 6 shows that b3N265S ho-
momers indeed possess a b1 phenotype: Pentobarbital
caused no inward current. Sensitivity to pentobarbital,
etomidate, and propofol can be conferred on b1 ho-
momers by a single amino acid substitution, which is
then necessary and sufficient for the expression of this
phenotype. This position will be referred in the subse-
quent text as the S/N site (for serine–asparagine site
FIG. 2. A scheme of b1/b3 chimeras. Open bars represent the parent b1 subunit sequence, and solid bars represent the b3 subunits.
The four transmembrane segments (M1–M4) are shown as light gray. The restriction enzyme sites used in constructing the chimeras are
labeled. The asterisks (to the right of the bars) identify chimeras that, when expressed as homomeric receptors, are responsive to
pentobarbital. At the bottom is the amino acid sequence from b1 (top) and b3 (bottom) subunits in the critical region responsible for the
difference in response to pentobarbital defined by the chimeras. The serine-265 and isoleucine-283 on the b1 subunit selected for
site-directed mutagenesis are underlined.
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corresponding to amino acid 265 on the b3 wild-type
subunit).
The effect of four other amino acids—alanine, gly-
cine, threonine, and glutamine—at the S/N site was then
investigated in the b3 subunit. These four substitutions
were chosen because of their side chains. Alanine has a
methyl group, and in general its substitution in an a-helix
is well tolerated (Overington, 1992). Glycine has the
minimal possible side chain, offering a single hydrogen,
and is known to be poorly tolerated in a-helices (Over-
ington, 1992). Threonine, like serine, has a hydroxyl-
containing side chain. Glutamine is a conservative sub-
stitution for the asparagine present in the wild-type b3
subunit. None of the above mutants, when expressed as
homomers, responded to pentobarbital (n 5 5 cells for
each mutation from two separate injections). When co-
expressed with the a1 subunit, however, all responded to
both pentobarbital and GABA. Thus, only b subunit
homomeric receptors with an asparagine residue at the
S/N site respond to the intravenous general anesthetics
used in these experiments.
Dominant role of serine at the S/N site in receptor
function
Functional recombinant homomeric receptors, like na-
tive heteromeric receptors, are thought to be pentamers
(Amin and Weiss, 1996). If we assume all five positions
to be equivalent, there are six possible combinations of
wild-type and mutant subunits (Table 3). To determine
the minimal proportion of wild-type b3 subunits neces-
sary to preserve the response to pentobarbital, different
mixtures of cRNA for b3 wild-type and for b3N265S
mutant were injected, ranging from all wild-type to all
mutant. For this analysis we assume that (a) subunit
expression is proportional to the amount of injected
cRNA for both wild-type and mutants, (b) the amount of
cRNA injected into each oocyte is known accurately
enough to allow comparison of averaged values, and (c)
wild-type and mutant subunits associate freely with
equal probabilities. Finally, we assume that the total
current reflects the averaged contribution of all the indi-
vidual channels present in the cell. Using the binomial
equation, we can then calculate the relative proportions
of the six different pentamers expected for each of the
mixtures used (see Table 3).
The probability of each pentamer for a given subunit
mixture ratio is shown in Fig. 7A. Curve 5 represents the
probability of finding a pentaoligomer with all five wild-
type subunits, curve 4 that with four wild-type and one
mutant, and so on. The curve for the all-mutant pentamer
is not shown; it is the mirror image of curve 5. The
probability of finding a pentaoligomer of a particular
subunit combination is shown in Fig. 7B. For example,
the probability of finding a pentamer with either four or
FIG. 4. Pentobarbital induces current in the b1S265N point mu-
tant. A: Current elicited by increasing concentrations of pento-
barbital applied to an oocyte injected with the b1S265N point
mutant cRNA is shown. Note the characteristic “off-response”
seen as an increase in the current on washout of the high
concentration of pentobarbital. B: The solid line shows the best
fit of the responses of four to six oocytes to the Hill equation with
the two parameter values noted. Data from 2.5 mM pentobarbital
were not included in the fit because of the decrease in the peak
current at this concentration. The dotted line is the best-fitting
dose–response curve for the b3 wild-type (EC50 5 81 6 9 mM, nH
5 0.94 6 0.8) taken from Cestari et al. (1996).
FIG. 3. Responses to pentobarbital applications in b1/b3 chime-
ras. Current response to application of 50 (left) or 500 mM (right)
pentobarbital in oocytes with homomeric chimeric GABA recep-
tors is shown. Nonresponsive chimeras (III and V) showed an
outward-going (upward) current, suggesting blockade of spon-
taneously opening receptors similar to those in the b1 wild-type
homomers. Chimera numbers are those shown in Fig. 2.
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more wild-type subunits is represented by curve b, which
is a simple sum of curves 5 and 4 from Fig. 7A. When
pentobarbital is applied to cells with different ratios of
subunits, the relationship between current and subunit
ratio should match one of the curves in Fig. 7B, depend-
ing on the number of wild-type subunits required for
pentobarbital sensitivity.
Pentobarbital at 250 mM, sufficient to maximize chan-
nel activation and minimize blockade, was applied to
oocytes (n 5 7 cells for each group) injected with six
different wild-type-to-mutant ratios of cRNAs, ranging
from 1.0 to 0, and the peak current was measured. Figure
7C shows the normalized peak currents observed for the
different ratios of wild-type b3 to b3N265S cRNA. (Ac-
tual current magnitudes obtained for each cRNA injec-
tion ratios were normalized by the average response to
100% wild-type b3-injected oocytes.) The results are
clearly consistent with a dominant behavior of the mu-
tated subunit: Only receptors with all five wild-type
subunits contribute to the response (compare Fig. 7B,
curve a with Fig. 7C). The inclusion of only one mutant
subunit lacking the critical asparagine residue is suffi-
cient to render the receptor nonresponsive.
Significance of b subunit S/N site in heteromeric
receptors
With the functional significance of the b subunit S/N
site in b subunit homomers defined, we investigated
whether this particular residue affects pentobarbital gat-
ing of current in heteromeric GABAA receptors. Wild-
type b1 and b3, and their respective S/N site mutants,
were coexpressed with a wild-type a1 subunit. Pentobar-
bital directly induced currents in all four subunit combi-
nations: a1b1wt, a1b1(S/N), a1b3wt, and a1b3(N/S). The
EC50 and Hill slopes for the four subunit combinations
did not statistically differ from one another (Fig. 8).
Therefore, although pentobarbital gating of homomeric b
receptors is profoundly influenced by the S/N site resi-
due, in heteromeric receptors the amino acid at this site
has no effect.
Belelli et al. (1997) reported that the S/N site residue
influences the degree of GABA current potentiation by
the intravenous general anesthetic etomidate. We there-
fore examined the effect of both etomidate and pento-
barbital on the potentiation of GABA-induced current in
the same four heteromeric receptors. Figure 9A shows
that coapplication of etomidate or pentobarbital with
GABA potentiated the GABA-induced current in all
subunit combinations. Receptors with b3wt or b1(S/N)
subunits showed significantly greater potentiation by eto-
midate than receptors containing b1wt or b3(N/S) subunits
(Fig. 9B), confirming the results of Belelli et al. (1997).
It is interesting that pentobarbital also showed subunit-
dependent potentiation of GABA-induced current, but
the potentiation was greater with either b1 or b3 wild-
type subunits than with either of the mutants (Fig. 9C).
Lastly, we explored whether the particular amino acid
at the S/N site had a dominant effect on etomidate’s
potentiation of the GABA-induced current. This issue is
important because naturally occurring heteromeric re-
ceptors most likely contain a mixture of b subunit iso-
forms (Benke et al., 1994; Li and De Blas, 1997). The
logic of the procedure was identical to that used to
demonstrate the dominant effect of the S/N site amino
acid in pentobarbital gating of homomeric receptors (Fig.
7). We varied the ratio of b3wt to b3(N/S) mutant cRNA
combined with fixed amounts of a1 and g2 subunit
cRNAs. Figure 10A shows etomidate potentiation of
GABA-induced currents in oocytes with wild-type
a1b3g2 (bottom) and mutant a1b3(N/S)g2 (top) penta-
FIG. 5. Etomidate (Etom) and propofol (Prop) cause current flow
in the b1S265N point mutant homomeric receptor. Pentobarbital
(Pento; 125 mM ) failed to induce a current in the b1 wild-type
(wt)-injected oocyte (A) but induced an inward-going current in a
b1S265N point mutant-injected oocyte (B). Etom (100 mM; C)
and Prop (300 mM; D) also elicited current flow in the b1S265N
homomeric receptor. The responses for the point mutant are
from different oocytes and were verified in at least four oocytes
from two separate injections. Calibration bar 5 0.5 mA for A and
B, 0.24 mA for C, and 1.0 mA for D.
FIG. 6. The b3N265S (b3NS) point mutant does not respond to
pentobarbital. Pentobarbital elicits inward-going current when
applied to the b3 wild-type (wt) homomeric receptor (top) but not
the b3NS point mutant (bottom). The point mutant shows an
outward-going (upward) current during pentobarbital applica-
tion, just like the b1 wt homomeric receptor (see Fig. 1). Com-
parable observations were made in six oocytes injected with this
point mutant.
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meric receptors. In heteromeric receptors of a1bxg2 com-
position, etomidate potentiation was greater for b3wt than
for b3(N/S), similar to the finding for the a1bx receptors
above (Fig. 9). As the proportion of mutant b3(N/S) sub-
units relative to b3wt subunits increased, the degree of
etomidate potentiation decreased (Fig. 10B). Assuming
that heterooligomeric receptors composed of a, b, and g
subunits assemble in a 2:2:1 ratio (Chang et al., 1996),
the relative number of pentamers containing two b3wt,
one b3wt and one b3(N/S), or two b3(N/S) subunits was
calculated from the binomial distribution (see Fig. 10 and
Table 3). The etomidate potentiation data are best ap-
proximated by the b3(N/S) dominant phenotype model
(Fig. 10B, dotted line).
DISCUSSION
Homomeric b subunit receptors
Functional receptors in the ligand-gated ion channel
superfamily are usually heteromeric, composed of two or
more types of subunits. The homomeric receptor formed
of murine GABAA b3 subunits is unique, in that it does
not respond to the natural ligand GABA but is gated by
other ligands instead. Because of the structural homology
among members of this superfamily, there may be other
homomeric receptors opened by an unexpected ligand.
Previously we reported that murine b3 homomeric
GABAA receptors possess functional chloride iono-
phores gated by several intravenous general anesthetics
but not by GABA (Cestari et al., 1996); this observation
was subsequently confirmed by Wooltorton et al. (1997).
In contrast, murine b1 homomeric GABAA receptors
(having 82% amino acid identity with b3 subunits) are
not gated by these anesthetics (Cestari et al., 1996).
We exploited the dramatic difference in responsiveness
to pentobarbital of the b1 and b3 homomers to identify a
single amino acid near the outer mouth of M2, the S/N site,
as the critical determinant of this pharmacological differ-
ence. The pentobarbital-induced current was abolished
when the asparagine-265 normally present on the b3 sub-
unit was replaced by serine normally present at the same
position on the b1 subunit. Conversely, mutation of b1
serine-265 to asparagine resulted in a receptor responsive to
pentobarbital and also to propofol and etomidate, two other
intravenous general anesthetics of different chemical
classes. Thus, the identity of a single amino acid alters the
responsiveness of the homomeric receptor to three different
intravenous general anesthetics.
The same GABAA receptor b subunit S/N site has
previously been reported to alter the loreclezole (Win-
grove et al., 1994), b-carboline (Stevenson et al., 1995),
volatile general anesthetic (Mihic et al., 1997), and eto-
midate (Belelli et al., 1997) potentiation of GABA-in-
duced currents and alcohol modulation of glycine recep-
tors (Wick et al., 1998; Ye et al., 1998). Wingrove et al.
(1994) found less loreclezole modulation of GABA-
induced current in b1-containing receptors than in b2- or
b3-containing receptors and that this difference depended
on the S/N site residue. Asparagine resulted in a greater
degree of potentiation than serine. These authors con-
cluded that the S/N site is part of the loreclezole binding
site, a site also shared by the b-carbolines. Mihic et al.
(1997), starting from the observation that enflurane, a
volatile general anesthetic agent, enhances glycine a1 but
inhibits GABA r1 homomeric receptors, converged on
two residues near the outer M2–M3 linker region as the
critical determinant of the allosteric action. Our S/N site
corresponds to their M2 domain residue.
Because the S/N site is involved in allosteric modula-
tion by several chemically diverse drugs, it is difficult to
see how the amino acid at the S/N site could participate
in forming the actual binding site. Furthermore, applica-
tion of the substituted-cysteine-accessibility technique to
the GABAA receptor a subunit has identified the amino
acids in the M2 domain with side chains exposed to the
TABLE 3. Theoretical distribution of the wild-type and mutant subunits in a
pentameric receptor oligomer based on the binomial distribution for different
ratios of subunit availability
Wild-type:
mutant ratio
Fraction of each combination
1:4 0.0003 0.006 0.051 0.205 0.410 0.327
2:3 0.010 0.077 0.230 0.346 0.259 0.078
3:2 0.078 0.259 0.346 0.230 0.077 0.010
4:1 0.327 0.410 0.205 0.051 0.006 0.0003
The combinations represent a bx pentameric assembly. The open and solid circles represent
the wild-type and the mutant subunits, respectively. The calculation is based on a random
incorporation of each subunit, where the probability of incorporation is determined by the
availability of the subunits, i.e., a binomial distribution b(x) 5 S[n!/x!(n 2 x)!]px (1 2 p)(n 2 x),
where n 5 5, p is the probability of finding a wild-type for a given injection ratio, and n is the
number of wild-type subunits in a pentamer. This holds true because each subunit necessarily has
to be a wild-type or a mutant. It is assumed that all receptors are pentamers and that all subunit
positions within the oligomer are equivalent.
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aqueous pore (Xu and Akabas, 1996). When the residues
within M2 are plotted on an a-helical wheel representa-
tion, residues susceptible to sulfhydryl reagents lie on the
lumen (Xu and Akabas, 1996). In this arrangement, the
position corresponding to the S/N site is located on the
opposite side, away from the aqueous lumen. Because
general anesthetic molecules are very lipophilic, how-
ever, this observation alone cannot exclude the S/N site
as part of the binding site.
A more parsimonious interpretation is that mutations in
the region of the S/N site may interfere with the conforma-
tional changes occurring during normal gating and alloste-
ric modulation. This interpretation is supported by a recent
report that etomidate potentiation of [3H]flunitrazepam
binding in an a1b3g2 receptor is abolished by the same
asparagine to serine mutation at the S/N site in the b3
subunit (Moody et al., 1997). Other evidence supporting the
effect of this region of M2 on allosteric modulation is the
report of Birnir et al. (1997). They found that mutation of a
conserved threonine (M2 129 locus) residue located only
three amino acids toward the cytoplasmic face from the S/N
site to glutamine abolished pentobarbital potentiation of
GABA-induced current in an a1b1 heteromeric receptor.
Overall, these findings are consistent with the conclusion of
Ueno et al. (1997) that the process of transduction of ago-
nist-binding site occupancy into channel opening requires
specific residues in the b subunit.
The M2 role in receptor function
The importance of the M2 domain to channel function
derives both from its role in forming the wall of the ion
FIG. 8. Pentobarbital concentration–response curve of b subunit
wild-type (wt) and b subunit point mutant a1b heteromeric recep-
tors. A: Concentration response curves of heteromeric receptors
containing b1 wt (©) and b1 mutant (sn) heteromers (–E–). B:
Concentration–response curves of b3 wt (©) and b3 mutant (ns)
heteromers (–E–). Lines represent the best fit to the Hill equation.
FIG. 7. The serine residue at the S/N site exerts a negative-
dominant effect on pentobarbital-gating of current. A: Probabil-
ity of finding pentamers with different composition [all wild-type
(curve 5), four wild-type and one mutant (curve 4), etc.] for
different ratios of wild-type to mutant cRNA assuming binomial
distribution of individual subunits. B: Joint probability of finding
(curve a) a pentamer with all wild-type subunits, (curve b) a
pentamer with at least four wild-type subunits (and therefore no
more than one mutant), (curve c) a pentamer with at least three
wild-type subunits (and no more than two mutants), etc., as a
function of different ratios of wild-type to mutant cRNA. Note
that curve b is the sum of curves 5 and 4 shown in A. C: Average
current (n 5 7 for all ratios) induced by 125 mM pentobarbital
from oocytes injected with different ratios of b3 wild-type and
b3N265S cRNA. The current values were normalized to the
average response at a ratio of 1.0 (all wild-type), which was 563
6 73 nA. The solid line represents the current predicted if only
receptors with all wild-type subunits were functional (see Table
3), assuming a binomial distribution of wild-type and mutant
subunits in pentameric oligomers.
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pores, crucial in defining permeation properties, and
from its role in the conformational changes associated
with different states of the channel. Direct evidence for
these conformational changes was provided by observa-
tion of alteration in the relative position of the M2
a-helical region of the nicotinic acetylcholine receptor in
resting receptors compared with activated receptors (Un-
win, 1993, 1995). The homology among the members of
the ligand-gated ion channel superfamily makes it likely
that the M2 domain of the GABAA receptor also under-
goes conformational changes during receptor activation
(Smith and Olsen, 1995). Receptor processes that depend
on a specific conformational state would be affected, thus
explaining how different aspects of receptor function are
modified without requiring a common binding site.
Similarly, mutation of the glycine receptor a1 subunit
at a position four residues away from the S/N site alters
the affinity of several ligands, both agonists and antag-
onists. Some amino acid substitutions cause changes in
distribution of the conductance levels of the receptor
(Rajendra et al., 1994; Laube et al., 1995; Lynch et al.,
1995). Because these point mutations have multiple ef-
fects on receptor function, Rajendra et al. (1994) con-
cluded that this position is crucial for both the integration
of information from agonist and antagonist binding sites
and its transmission to the activation gate of the receptor.
Dominant role of S/N site: topology and functional
implications
Substitution of glycine, threonine, glutamine, or serine
at the S/N site in the b3 subunit did not reproduce the
wild-type phenotype. Because the b3 subunit is known to
be glycosylated (Buchstaller et al., 1991), the require-
ment for asparagine suggests a possible role of N-linked
glycosylation. However, asparagine-265 is not within the
N-linked glycosylation consensus sequence (Kornfeld
and Kornfeld, 1986; Parekh et al., 1989) and probably
FIG. 10. The b subunit S/N site amino acid exerts a dominant
effect on etomidate (Etom) potentiation of a1bxg2 heteromeric re-
ceptors. Xenopus oocytes were injected with b3(N/S) or b3wt cRNA
with a fixed amount of a1 and g2 cRNA. Etom potentiation of
current evoked by GABA (G; EC20 dose) was examined. A: The
current traces show control G alone (left), coapplication of GABA
and 10 mM Etom (middle), and G alone (right). Etom potentiation of
b3wt-containing abg trimeric receptors was greater, as was ob-
served for the ab dimeric combination (Fig. 7). B: Increasing pro-
portions of b3wt cRNA compared with b3(N/S) cRNA were injected in
a dimeric combination with a1 and g2 cRNA. The decrease in
potentiation with increasing proportion of the point mutant was
much better approximated by a b3(N/S)-dominant binomial model
(dotted line) than by a b3wt-dominant model (dashed line). Data are
mean 6 SE (bars) values (no. of assays).
FIG. 9. The b subunit S/N site amino acid determines etomidate
but not pentobarbital potentiation of a1b heteromeric receptors.
Etomidate but not pentobarbital potentiation of GABA-induced
current is dependent on the b subunit M2 domain amino acid. A:
Four groups of Xenopus oocytes were injected with b1wt, b1(S/N),
b3wt, or b3(N/S) cRNA with an equal amount of a1wt cRNA. GABA
(G; respective EC20 dose) was applied alone or with the intrave-
nous general anesthetic etomidate (E; 10 mM ) or pentobarbital
(25 mM ). These anesthetics potentiated the GABA-induced cur-
rent in all subunit combinations examined. However, the mag-
nitude of potentiation was subunit-dependent. B and C: Sum-
mary of anesthetic potentiation. Data are mean 6 SEM (bars)
values from six oocytes for each combination. Etomidate, but
not pentobarbital, potentiation of GABA-induced current is con-
trolled by the critical S/N amino acid. Differences are significant
at p , 0.05. wt, wild-type; sn and ns, mutant.
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projects into the lipid domain away from the aqueous ion
channel or the extracellular surface.
The wild-type-to-mutant cRNA ratio experiment shows
that the functional role of the S/N site is negative dominant,
so that the presence of a single nonfunctioning subunit
(such as the b3N265S mutant) within the pentameric as-
sembly is sufficient to abolish the pentobarbital-induced ion
channel opening. If the S/N site residue is considered to be
part of the pentobarbital binding site, its dominant role is
hard to understand unless the ion channel only opens when
pentobarbital occupies the sites in all five subunits. Such a
concordant interaction between five binding sites would be
manifested as a dose–response curve with a larger Hill
slope, which we did not find.
The experiments on the coexpression of wild-type and
mutated b3N265S can also be best interpreted in terms of
the involvement of this site in conformational changes of
the receptor. By varying the proportions of wild-type b3
and activation-defective b3N265S, we found that the
inclusion of only one mutant subunit in a pentameric
receptor was sufficient to block activation by pentobar-
bital. Unwin (1995) proposed that, for the nicotinic ace-
tylcholine receptor, all five subunits need to rotate at the
level of the M2 region, which allows for the open con-
figuration to be stabilized by interactions between the
helices around the pore. If a similar conformational
change takes place in these homomeric receptors, the
inability of even one of the subunits to assume or remain
at this alternative position would preclude the open state,
consistent with a negative dominant role for the serine
residue at the S/N site.
Role of S/N site in heteromeric receptors
In contrast to homomeric receptors, where the b subunit
S/N residue strongly affects anesthetic gating, the S/N site
only partially controls the GABA-gated current in hetero-
meric receptors. The effect of etomidate in heteromeric
GABAA is b subunit-dependent (Hill-Venning et al., 1997;
Sanna et al., 1997); the effect of pentobarbital is not
(Thompson et al., 1996; Sanna et al., 1997). Our results
extend these observations and confirm the finding of Belelli
et al. (1997) that the amino acid at the S/N site determines
the different actions of etomidate at receptors with different
b subunits. Other subunit combination and site-directed
mutagenesis studies have shown that direct gating by intra-
venous general anesthetics has different receptor structural
requirements than the indirect ligand-gated current-potenti-
ating actions (Davies et al., 1997; Moody et al., 1997;
Uchida et al., 1997). One parsimonious interpretation is that
intravenous general anesthetics do not open a homomeric
receptor the same way a ligand opens a heteromeric recep-
tor. Because b3 homomers are spontaneously active even in
the absence of GABA (Cestari et al., 1996; Wooltorton
et al., 1997), pentobarbital or other allosteric potentiators
might increase the current simply through potentiation of
spontaneously opening channels. In heteromeric receptors,
which show negligible spontaneous opening in the absence
of GABA (Angelotti and Macdonald, 1993), the same
structural determinants that correlate with homomeric gat-
ing manifest as allosteric potentiation. This interpretation of
homomeric receptor function cannot, however, explain the
observation that pentobarbital and etomidate, both known
to potentiate GABA-induced current in heteromers, fail to
induce any significant current in b1 homomers, even though
they also open spontaneously (see present study, Fig. 1;
Krishek et al., 1996). Further studies are necessary to define
this complex relationship between homomeric and hetero-
meric receptor functions.
In summary, we have identified a particular asparagine
residue in the M2 portion of the GABAA receptor b3
subunit as the critical determinant for current generation
by pentobarbital and two other intravenous general an-
esthetics. We favor the interpretation that this particular
residue plays an essential role in the ion channel trans-
duction process. We think it unlikely that it forms a
binding pocket common to many compounds of diverse
chemical structures. The same amino acid regulates the
magnitude of allosteric potentiation by etomidate but not
pentobarbital in heteromeric receptors. Further investi-
gation of the pharmacological and physiological similar-
ities and differences between homomeric and hetero-
meric receptors may lead to a deeper understanding of
subunit interactions inherent in the function of these
complex oligomeric GABAA receptors.
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